Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies

Hermans, Michel P.; Bouenizabila, Evariste; Amoussou-guenou, Daniel K.; Ahn, Sylvie A.; Rousseau, Michel F.

doi:10.1186/s12933-015-0226-z

Cardiovascular Diabetology

Table 3 Baseline characteristics

From: Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies

Study^§	Age (years)	Males (%)	Diabetes type & duration (years)		HbA1c (%)	TC (mg/dL)	LDL-C (mg/dL)	HDL-C (mg/dL)	Non-HDL-C (mg/dL)	apoB (mg/dL)	TG (mg/dL)
4D	66	54	T2DM	18	6.7	218	125	36	182	~	261
4S	59	81	~			260	188	46	214	~	132
diabetes substudy	60	78	~			259	186	43	216	~	150
ACCORD-Lipid	62	69	T2DM	10	8.3	175	100	38	137	~	164
ADDITION-Europe	60.3	58	T2DM	0	7	214	133	46	168	~	146
AFCAPS/TexCAPS	58	85	T1DM; T2DM			221	150	37	184	~	158
AIM-HIGH	64	85	~		6.7	146	74	35	111	83	168
AleCardio	60.8	73	T2DM	8.6	7.8	152	79	42	110	~	152
ALERT	50	66	~			247	158	50	197	~	195
ALLHAT-LLT	66	51	T2DM			224	146	48	176	~	152
Alpha-Omega	69	78	~			183	100	50	133	~	146
ASCOT-LLA	63	81	~			212	131	50	162	~	150
diabetes substudy	63.6	76	T2DM			205	128	46	159	~	168
ASPEN	61	66	T2DM	8	7.8	194	113	47	147	~	147
AURORA	64	62	~			176	100	45	131	82	157
diabetes substudy	65	66	~			174	97	43	131	~	168
BIP	60	91	T2DM			212	148	35	177	~	145
CARDS	62	68	T2DM	8	7.9	207	117	54	153	117	173
CARE	59	86	~			209	139	39	170	~	156
diabetes substudy	61	80	~			206	136	38	168	~	164
CDP (clofibrate)		100	~			252	~	~	~	~	183
CDP (niacin)		100	~			253	~	~	~	~	183
dal-OUTCOMES	60.2	81	~			145	76	42	103	81	134
DIS	46	56	T2DM	0		218	~	~	~	~	157
FIELD	62	63	T2DM	5	6.9	195	119	43	152	97	173
GISSI-Prevenzione	60	86	T2DM (79 %) T1DM (21 %)			229	152	46	183	~	166
GREACE		79	~			264	193	39	225	~	159
diabetes substudy	55	56	T2DM (92 %) T1DM (8 %)	10.5	7.5	271	189	35	236	~	221
HATS	53	87	~			200	128	30	170	119	219
HHS	47	100	~			270	189	47	223	~	175
diabetes substudy	49	100	T2DM	4.5		292	200	46	246	~	214
HPS - MRC/BHF		75	~			228	131	41	187	114	186
diabetes substudy	62.1	70	T2DM (90 %) T1DM (10 %)	27	7	220	124	41	179	110	204
HPS2-THRIVE	64.9	82.7	~			128	63	44	84	68	127
IDEAL	62	81	~			197	122	46	151	119	151
ILLUMINATE	61.3	77.8	T2DM			157	80	49	108	73	127
JELIS	61	31.4	~			275	181	59	216	~	153
LEADER	68	100	~			218	131	46	172	~	213
LIPID	62	83	~			218	150	36	182	133	142
LIPS	60	84	T2DM; T1DM			200	131	38	162	~	160
MEGA	58.3	32	~			242	157	58	184	~	128
ORIGIN	63.5	65	T2DM	5.4		189	112	46	143	~	142
PERFORM	67.2	62.5	~			~	93	~	~
Post-CABG	61.7	92	~			226	156	39	187	~	158
PREDIMED	67	43	~			219	143	53	172	102	142
PROACTIVE	61.8	66	T2DM	9.5	8.1	199	114	45	154	~	198
PROFIT-J	85	65	T2DM	11.3	7.4	198	115	55	144	~	141
PROSPER	75	48	~			220	147	50	170	~	133
RPS	63.9	61.5	~		6.7	216	132	51	165	~	150
SHARP	62	63	~			189	107	43	146	92	205
STABILITY	65	81	~			~	80	45	~
STENO-2	54.9	74	T2DM	5.8	8.6	210	133	40	170	~	159
TNT	61	81	~			175	97	47	128	111	151
diabetes substudy	63	73	~	8.5	7.4	175	96	45	130	113	171
VA Cooperative Study	55	100	~			244	~	~	~	~	~
VA-HIT	64	100	~			175	111	32	143	96	161
diabetes substudy	65		~			172	108	31	141	~	166
mean	61.7	74		7.5	7.49	209	126	44	161	99	162
standard deviation	6.4	17		4.9	0.68	34	32	7	32	19	27

^§: see legend to Table 1 for study acronyms definition; apoB: apolipoprotein B100; C: cholesterol; HbA1c: glycated haemoglobin A1c; HDL: high-density lipoprotein; LDL: low-density lipoprotein; T1DM and T2DM: type 1 and type 2 diabetes mellitus; TG: triglycerides

Back to article page

ISSN: 1475-2840

Contact us

Submission enquiries: journalsubmissions@springernature.com